Xi Chen1, Enrique Maldonado1, Ralph A DeFronzo1,2, Devjit Tripathy1,2. 1. Department of Medicine, Diabetes Division, University of Texas Health Science Center, San Antonio, TX, USA. 2. Audie L Murphy VA Hospital, South Texas Veterans Health Care System, San Antonio, TX, USA.
Abstract
AIM: To examine the relationship between plasma glucagon levels and insulin sensitivity and insulin secretion in obese subjects. METHODS: Suppression of plasma glucagon was examined in 275 obese Hispanic Americans with varying glucose tolerance. All subjects received a 2-hour oral glucose tolerance test (OGTT) and a subset (n = 90) had euglycemic hyperinsulinemic clamp. During OGTT, we quantitated suppression of plasma glucagon concentration, Matsuda index of insulin sensitivity, and insulin secretion/insulin resistance (disposition) index. Plasma glucagon suppression was compared between quartiles of insulin sensitivity and beta-cell function. RESULTS: Fasting plasma glucagon levels were similar in obese subjects with normal glucose tolerance (NGT), prediabetes, and type 2 diabetes (T2D), but the fasting glucagon/insulin ratio decreased progressively from NGT to prediabetes to T2D (9.28 ± 0.66 vs 6.84 ± 0.44 vs 5.84 ± 0.43; P < 0.001). Fasting and 2-hour plasma glucagon levels during OGTT progressively increased and correlated positively with severity of insulin resistance (both Matsuda index and euglycemic hyperinsulinemic clamp). The fasting glucagon/insulin ratio declined with worsening insulin sensitivity and beta-cell function, and correlated with whole-body insulin sensitivity (Matsuda index, r = 0.81; P < 0.001) and beta-cell function (r = 0.35; P < 0.001). The glucagon/insulin ratio also correlated and with beta-cell function during OGTT at 60 and 120 minutes (r = -0.47; P < 0.001 and r = -0.32; P < 0.001). CONCLUSION: Insulin-mediated suppression of glucagon secretion in obese subjects is impaired with increasing severity of glucose intolerance and parallels the severity of insulin resistance and beta-cell dysfunction. Published by Oxford University Press on behalf of the Endocrine Society 2021.
AIM: To examine the relationship between plasma glucagon levels and insulin sensitivity and insulin secretion in obese subjects. METHODS: Suppression of plasma glucagon was examined in 275 obese Hispanic Americans with varying glucose tolerance. All subjects received a 2-hour oral glucose tolerance test (OGTT) and a subset (n = 90) had euglycemic hyperinsulinemic clamp. During OGTT, we quantitated suppression of plasma glucagon concentration, Matsuda index of insulin sensitivity, and insulin secretion/insulin resistance (disposition) index. Plasma glucagon suppression was compared between quartiles of insulin sensitivity and beta-cell function. RESULTS: Fasting plasma glucagon levels were similar in obese subjects with normal glucose tolerance (NGT), prediabetes, and type 2 diabetes (T2D), but the fasting glucagon/insulin ratio decreased progressively from NGT to prediabetes to T2D (9.28 ± 0.66 vs 6.84 ± 0.44 vs 5.84 ± 0.43; P < 0.001). Fasting and 2-hour plasma glucagon levels during OGTT progressively increased and correlated positively with severity of insulin resistance (both Matsuda index and euglycemic hyperinsulinemic clamp). The fasting glucagon/insulin ratio declined with worsening insulin sensitivity and beta-cell function, and correlated with whole-body insulin sensitivity (Matsuda index, r = 0.81; P < 0.001) and beta-cell function (r = 0.35; P < 0.001). The glucagon/insulin ratio also correlated and with beta-cell function during OGTT at 60 and 120 minutes (r = -0.47; P < 0.001 and r = -0.32; P < 0.001). CONCLUSION: Insulin-mediated suppression of glucagon secretion in obese subjects is impaired with increasing severity of glucose intolerance and parallels the severity of insulin resistance and beta-cell dysfunction. Published by Oxford University Press on behalf of the Endocrine Society 2021.
Authors: Rachel A Jamison; Romana Stark; Jianying Dong; Shin Yonemitsu; Dongyan Zhang; Gerald I Shulman; Richard G Kibbey Journal: Am J Physiol Endocrinol Metab Date: 2011-08-23 Impact factor: 4.310
Authors: Jennifer H Stern; Gordon I Smith; Shiuwei Chen; Roger H Unger; Samuel Klein; Philipp E Scherer Journal: J Endocrinol Date: 2019-11 Impact factor: 4.286
Authors: Rodolfo Guardado-Mendoza; Alberto O Chávez; Lilia M Jiménez-Ceja; Andrea Hansis-Diarte; Ralph A DeFronzo; Franco Folli; Devjit Tripathy Journal: Acta Diabetol Date: 2016-09-13 Impact factor: 4.280
Authors: Jiudan Zhang; Olga Pivovarova-Ramich; Stefan Kabisch; Mariya Markova; Silke Hornemann; Stephanie Sucher; Sascha Rohn; Jürgen Machann; Andreas F H Pfeiffer Journal: Front Nutr Date: 2022-05-19